Phosphoric Acid

Phosphoric Acid

SCHEMBL1692291

O=P(O)(O)O.O=S(=O)(O)O.[NaH].[NaH]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 2/20 0.55
CA5B Q9Y2D0 2/20 0.55
TSHR P16473 3/20 0.36
CA2 P00918 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CA1 P00915 1/20 0.36
NT5E P21589 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
BLM P54132 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC34A1 Q06495 1/20 0.33
MMP2 P08253 1/20 0.31
THRB P10828 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL1326320 1.00 CA5A (0.55) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL5343874 1.00 CA5A (0.55) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28164160 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28270321 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL27635906 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL6231084 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL5340898 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL29268866 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL20914382 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1
Phosphoric Acid SCHEMBL28268676 0.96 CA5A (0.50) CA5ACA5BTSHRCA2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023218472-A1 AN AQUEOUS OPHTHALMIC SOLUTION OF NSAIDS AND FLUOROQUINOLONE ANTIBIOTIC AND PROCESS OF PREPARATION THEREOF AKUMS DRUGS & PHARMACEUTICALS LIMITED (IN) 2023-11-16 WO claimed
WO-2024142116-A1 STABLE PHARMACEUTICAL COMPOSITION FOR OTITIS EXTERNA SENTISS PHARMA PRIVATE LIMITED (IN) 2024-07-04 WO disclosed
US-11844832-B2 Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production NAJIT TECHNOLOGIES, INC. (US) 2023-12-19 US disclosed
WO-2023218472-A1 AN AQUEOUS OPHTHALMIC SOLUTION OF NSAIDS AND FLUOROQUINOLONE ANTIBIOTIC AND PROCESS OF PREPARATION THEREOF AKUMS DRUGS & PHARMACEUTICALS LIMITED (IN) 2023-11-16 WO disclosed
CN-115337407-A Treatment of AMD using AAVSFLT-1 阿瓦兰克澳大利亚私人有限公司 2022-11-15 CN disclosed
US-20210196812-A1 INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION Najít Technologies, Inc. 2021-07-01 US disclosed
CN-111533900-A Plastic antibacterial agent and antibacterial plastic 朱金娥 2020-08-14 CN disclosed
CN-111454560-A Antibacterial polycarbonate plastic and preparation method thereof 朱金娥 2020-07-28 CN disclosed
CN-110475543-A Eye medicinal extended release preparation and application thereof MATI THERAPEUTICS INC 2019-11-19 CN disclosed
EP-3504227-A1 IDENTIFICATION OF MUTATIONS IN CHANNELOPSIN VARIANTS HAVING IMPROVED LIGHT SENSITIVITY AND METHODS OF USE THEREOF Wayne State University (US) 2019-07-03 EP disclosed
WO-2018044912-A1 IDENTIFICATION OF MUTATIONS IN CHANNELOPSIN VARIANTS HAVING IMPROVED LIGHT SENSITIVITY AND METHODS OF USE THEREOF WAYNE STATE UNIVERSITY (US) 2018-03-08 WO disclosed
US-20130267591-A1 NOVEL OPHTHALMIC COMPOSITIONS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2013-10-10 US disclosed
EP-2566453-A1 NOVEL OPHTHALMIC COMPOSITIONS Sun Pharma Advanced Research Company Ltd (IN) 2013-03-13 EP disclosed
WO-2011138801-A1 NOVEL OPHTHALMIC COMPOSITIONS SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210196812-A1 INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION OGG1, EIF2AK2, AS3MT CA5A 886/4885CA5B 656/4885TSHR 3359/4885
US-11844832-B2 Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production OGG1, EIF2AK2, AS3MT CA5A 886/4885CA5B 656/4885TSHR 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.